Effect of Fractional Microneedling Radiofrequency Versus Intralesional Steroid Injection With and Without Microneedling on Tissue Levels of PDGF & CTGF in Hypertrophic Scars: a Randomized Comparative Clinical Trial.
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Cairo University
- Enrollment
- 30
- Locations
- 2
- Primary Endpoint
- Calculation of patient and observer scar assessment scale (POSAS) to assess change of hyertrophic scars
Study Overview
Brief Summary
Comparing between the effect of Fractional Microneedling Radiofrequency Versus Intralesional Steroid Injection with and without Microneedling on Tissue levels of PDGF & CTGF in Hypertrophic Scars
Detailed Description
In each patient, each one of the two scars, or each side of a large scar will be assigned to one of the following treatment methods: 1-Fractional microneedling radiofrequency 2-Intralesional steroids injection. Scars treated with intralesional steroids will be subgrouped into two groups, one group treated with only intralesional steroids and the other group treated with intralesional steroids and followed by microneedling. Fractional microneedling radiofrequency parameters; Power: 6 v, Exposure time: 800 ms. Depth: 2.5 mm (using non-insulated micro-needles), Frequency: 2 Hz. For intralesional steroids injection, Triamcinolone acetonide will be injected in concentration 1:2 (20 mg/dl) using insulin syringe. Microneedling will be done using the same tip of the fractional microneedling radiofrequency at same depth. All patients will receive 5 treatment sessions 4 weeks apart.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients with mature hypertrophic scars.
- •Patients with age above 18 years.
- •Both males and females.
- •Patients with two separate lesions, each 3 cm length at least OR a large sized lesion 10 cm length at least.
Exclusion Criteria
- •Patients with unrealistic expectations.
- •Patients with active skin infections or autoimmune diseases.
- •Non-compliant patients.
- •Patients who had received any form of treatment for scars during the last six months.
- •Recent use of isotretinoin within six months prior to the procedures.
- •Patient with known allergy to lidocaine.
- •Pregnancy & Lactation.
Outcomes
Primary Outcomes
Calculation of patient and observer scar assessment scale (POSAS) to assess change of hyertrophic scars
Time Frame: 6 months
Calculation of patient and observer scar assessment scale (POSAS) before every session and one month after the last session to clinically assess change of hyertrophic scars
Photographic documentation will be performed to assess change of hypertrophic scar(s)
Time Frame: 6 months
Photographic documentation will be performed by obtaining digital photographs for hypertrophic scar(s) before every session and one month after the last session.
Measurement of tissue levels of both platelet derived growth factor (PDGF) & connective tissue growth factor (CTGF) to assess change of hypertrophic scars
Time Frame: 6 months
Measurement of tissue levels of both PDGF \& CTGF to assess change of hypertrophic scars. Tissue levels of both PDGF \& CTGF will be measured by PCR in biopsies obtained from the scar areas before the treatment sessions and one month after the last session
Secondary Outcomes
No secondary outcomes reported
Investigators
Maha Fathy Elmasry
principal investigator
Cairo University